The analysis of this study showed that the expression of stemness markers, such as CD133, Oct4, Nestin, and Sox2, was inhibited in GBM cells treated with retinoids, while the expression of Nestin and Sox2 was suppressed in VD3-treated GBM cells. This evidence concerns the gene SOX2 and glioblastoma.